Apellis Pharmaceuticals, Inc. (APLS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$41.030.00%
Close 2026-05-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Biogen finished buying Apellis, making it a full part of Biogen. Apellis aims for $689 million revenue in 2025. Revenue grew from $166.8 million to $268.3 million in early 2026. The company plans a share buyback to return value to shareholders.
Apellis is not yet profitable and lost key leaders after the merger. Revenue growth may slow below $1.5 billion by 2030. The merger could disrupt operations and delay financial improvements.
The market has no clear consensus or price targets after the Biogen acquisition. Our view sees potential but also risks from integration and profitability.
Breaks if: acquisition not completed or integration fails by mid-2026
Finalize the acquisition process to become a wholly owned subsidiary of Biogen.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as APLS operates in the healthcare sector with potential for significant upside but also faces notable risks. The current thesis state is intact, supported by recent improvements in financial performance.
The market appears to have priced in an expensive valuation, reflecting high expectations for future growth. Investors seem to anticipate continued strong performance, despite the company's current loss-making status.
Fundamentals are likely to improve, given the recent revenue growth from $166.8 million to $268.3 million year-over-year. However, the company still faces moderate risk, especially with a recent decline in company quality and potential for earnings misses in a high-miss-rate industry.
The long-term thesis hinges on several factors, including the completion of the acquisition by Biogen and the performance of sector bellwethers like VRTX, REGN, and ARGX. Additionally, any cuts to guidance or worsening economic conditions could negatively impact APLS.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. There are no new supports or threats affecting the thesis. The recent financial performance remains strong, keeping the reason to own it intact. The total stock risk has risen, changing the risk label from 'moderate' to 'elevated'.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $689 million in FY25
Focus on enhancing financial metrics such as revenue and net income.
Newly stated in 2026-Q1. Revenue increased to $268.3 million in 2026-Q1 from $166.8 million in 2025-Q1, indicating a significant improvement in financial performance. This aligns with management's focus on enhancing financial metrics, showing positive trajectory.
“Revenue increased to $268.3 million in 2026-Q1.”
Breaks if: no buyback program started by mid-2026
Initiate a share buyback program as part of capital allocation strategy.
In the next 1-3 years, APLS's performance will depend on its ability to navigate sector dynamics and execute on management priorities. Not investment advice.